Surveillance of Kaletra in Korean Patients

Study Identifier
P11-068
CT.gov Identifier
NCT01083173
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    2 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients 2 years of age and above with HIV-1 infection * Patients who were prescribed Kaletra treatment as per investigator's medical judgment * Patients who gave verbal or written authorization to use their personal and health data * Patients who started Kaletra treatment after study agreement was in place
    Exclusion Criteria:
    * Patients with known hypersensitivity to lopinavir, ritonavir or any excipients of the Kaletra tablet * Patients who were being treated or will be treated with drugs that are contraindicated with Kaletra * Patients who have been treated with Kaletra * Patients participating in other clinical trials

    Protocol Summary

    This single-arm, multi-center, Post-Marketing Surveillance study of Kaletra (lopinavir/ritonavir) was conducted in accordance with the approved Korean product labeling in participants 2 years of age and older with human immunodeficiency virus type 1 (HIV-1) infection.

    Study Locations

    No locations found.